Clinical trial
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
The purpose of this trial is to determine
- Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
- Progression-free survival (PFS) 3 years after registration
| Category | Value |
|---|---|
| Study start date | 2014-07-11 |